Omnio raises 1.5M EUR in successful series A funding
SWEDEN, 8th November, 2022 — Omnio AB, a private biopharmaceutical company developing recombinant plasminogen to heal chronic wounds announces a successful 1.5M EUR funding round. The funds will be allocated to develop a manufacturing process for the recombinant plasminogen drug product and conduct efficacy studies of the drug candidate in animal models for wound healing. […]
Omnio AB raises 5.5MSEK in fundraising round
SWEDEN, 6th December, 2021 — Omnio AB is developing new drug products based on the proinflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to […]